An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis

• Status: Completed
• Trial end date: 2020-11-25
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of NTZ 500mg bid after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pinnacle Clinical Research, PLLC
• Treatments: Nitazoxanide

Criteria

Inclusion Criteria:

1. Males or females aged from 18 to 75 years inclusive the Screening Visit.

2. Must provide signed written informed consent and agree to comply with the study protocol.

3. Females participating in this study must be of non-childbearing potential or using highly efficient contraception for the full duration of the study

4. Histological confirmation of steatohepatitis on a diagnostic liver biopsy (biopsy obtained within 6 months prior to Screening or during the Screening Period) with at least 1 in each component of the NAS (steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3).

5. Fibrosis stage of 2 or 3, according to the NASH CRN fibrosis staging system on a diagnostic liver biopsy (biopsy obtained within 6 months prior to Screening or during the Screening Period).

Exclusion Criteria:

1. History of efficient bariatric surgery within 5 years prior to Screening, or planned bariatric surgery in the course of the study.

2. Patients with HbA1c >10.0%. If abnormal at the first Screening Visit, the HbA1c measurement can be repeated. A repeated abnormal HbA1c (HbA1c >10.0%) leads to exclusion.

3. Patients with a history of clinically significant acute cardiac event within 6 months prior to Screening such as: stroke, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).

4. Weight loss of more than 10% within 6 months prior to Randomization.

5. Patient with any history or presence of decompensated cirrhosis.

6. Current or recent history (<1 year) of significant alcohol consumption. For men, significant consumption is typically defined as higher than 30 g pure alcohol per day. For women, it is typically defined as higher than 20 g pure alcohol per day.

7. Current or history of other substance abuse within 1 year prior to screening.

8. Pregnant or lactating females or females planning to become pregnant during the study period.

9. Other well documented causes of chronic liver disease according to standard diagnostic procedures including, but not restricted to:

1. Positive hepatitis B surface antigen (HBsAg)

2. Positive HCV RNA, (tested for in case of known cured HCV infection, or positive HCV Ab at Screening)

3. Suspicion of drug-induced liver disease

4. Alcoholic liver disease

5. Autoimmune hepatitis

6. Wilson's disease

7. Primary biliary cirrhosis, primary sclerosing cholangitis

8. Genetic homozygous hemochromatosis

9. Known or suspected HCC

10. History or planned liver transplant, or current MELD score >15.

10. Patients who cannot be contacted in case of emergency.

11. Known hypersensitivity to the investigation product or any of its formulation excipients.

12. Patients who are taking warfarin or other highly plasma protein-bound drugs with narrow therapeutic indices.

13. Patients who are currently participating in, plan to participate in, or have participated in an investigational drug trial or medical device trial containing active substance within 30 days or five half-lives, whichever is longer, prior to Screening.

14. Evidence of any other unstable or, untreated clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic, or psychiatric disease.

15. Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.

16. History of noncompliance with medical regimens, or patients who are considered to be unreliable.

17. Positive anti-human immunodeficiency virus (HIV) antibody.

18. AST and/or ALT >10 x upper limit of normal (ULN).

19. Conjugated bilirubin >2.0 mg/dL due to altered hepatic function. Note: Gilbert Disease patients are allowed into the study.

20. INR >1.50 due to altered hepatic function.

21. Platelet count <100,000/mm3 due to portal hypertension.

22. Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney damage or eGFR of less than 60 ml/min/1.73 m2).